Appili gets FDA approval to expand the clinical trial of favipiravir
Category: #health  By Pankaj Singh  Date: 2020-08-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Appili gets FDA approval to expand the clinical trial of favipiravir

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application for favipiravir, a broad-spectrum antiviral. The company has planned to expand the second phase of the clinical trials of this antiviral into the U.S., intending to evaluate the safety and efficacy of favipiravir tablets towards controlling outbreaks after exposure to COVID-19 in long-term care facilities.

According to Dr. Armand Balboni, the CEO of Appili Therapeutics, the burden of disease in long-term care facilities continues to be a major issue, and finding ways to provide LTC staff and residents with protection against COVID-19 via an oral treatment would be a remarkable milestone in efforts to contain the devastating effects of this pandemic. He has further highlighted that the limited response to the vaccine is frequently observed in elderly people and this has been the chief reason for expanding the trial into the U.S.

Also, favipiravir would be administered in the oral form as a tablet, without the requirement to be given in the intravenous mode, and might prove to be a significant option for avoiding and controlling outbreaks in elderly people living in LTC centers, added Balboni.

As reported, the company’s Phase 2 clinical trials focus on leveraging whether favipiravir could be suitably administered as an oral tablet across a broad range of long-term care settings. The company has planned to enroll up to 760 participants in this second phase of clinical trials across both Canada and the U.S.

Dr. Allison McGeer, Senior Clinician Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health, has stated that, while the highest risk for contracting the disease lies with the elderly people, the currently surging rates of COVID-19 infection as evident in much of the U.S. are expected to be a major threat to people working and living in long-term care settings.

 

Source Credits:

https://www.businesswire.com/news/home/20200810005098/en/FDA-Clears-Appili-Therapeutics-Expand-Phase-2

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...

JCB unites with ACI Worldwide to boost merchant acquiring capabilities
JCB unites with ACI Worldwide to boost merchant acquiring capabilities
By Pankaj Singh

JCB International, a credit card company, has reportedly partnered with ACI Worldwide, a payment system company, to increase merchant acquiring capabilities across the globe.

The To...

Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand
Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand
By Pankaj Singh

Research and development in the global transcatheter heart valve replacement industry have been gathering pace in recent years, with the increasing occurrence of valvular heart diseases and the demand for less invasive...